Image Credit: Morningstar
The IGC Pharma Inc., the leading clinical-level biotechnology company accelerating AI to establish creative alternative treatments for alzheimer’s disease, have declared its extension of its running phase 2 CALMA clinical trial examining investigational drug candidate IGC-AD1 for agitation in alzheimer’s disease. The trial has launched a new site at the University of South Florida’s Department of Psychiatry and Behavioural Neurosciences, led by Dr Ram Bishnoi, the principal investigator. With this expansion clinical trial might have a sound space and resources sufficient to advance or add improvement to the key areas of the clinical trial.
The company's precious asset, IGC-AD1, is a companion to the phase 2 CALMA clinical trial. This is a huge development for the company to proceed confidently with the internal asset support. The expansion will double the strength and increase the credibility of this clinical trial and other operations. Further, the IGC Pharma is also known for its AI integration, while the clinical trial will be backed up with great support following the approach of the expansion and development.
The enrolment at the new site has started with the four participants enrolled so far. This is a crucial step towards leveraging hiring and improving the duration of the study. The CALMA phase 2 trial is a placebo-controlled, double-layered, randomised study examining the safety and efficacy of IGC-AD1 in mitigating agitation in Alzheimer's patients. With the integration of USF, the CALMA continues to extend throughout the various clinical sites based in North America.
The CEO of IGC Pharma, Ram Mukunda, said, “The inauguration of this site at the University of South Florida powers up our potential to hire diverse participants while promising a superior standard of clinical oversight. The USF introduce a robust academic pedigree, a well-developed record and deep expertise in behavioural neuroscience in clinical research. With the enrollment already ongoing, we’re excited to witness the consistent momentum in upgrading the CALMA trial.”
The university is a known clinical and academic institution committed to improving mental health via a unified motive of research, education and clinical care. The university was established in 1971 as USF’s first-ever native training program. The department has gained international and national recognition for its creative and spectacular ideas for curing addictive, behavioural and mental disorders.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
